Healthcare
Live Price
Offline$0.4219
+0.00% today
1Y Change
+67.95%
Window
Jun 20, 2025 → Jun 12, 2026
Coverage: 253 bars · Jun 20, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Venus Medtech (Hangzhou) Inc. (VMTHF) is a Healthcare stock with a market cap of $690.00M and listed on OTC. The stock last traded around $0.42 and up 68.0% across the available one-year price window (Jun 20, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -36.5%, EPS growth of +44.2%, a dividend yield of 0.0%. What stands out right now is revenue -36.5%, EPS +44.2%, free cash flow -1764.0% with operating margin -112.5% and ROIC -14.8%. Valuation is more restrained than many high-expectation growth names at price/sales 2.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VMTHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VMTHF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VMTHF Max Drawdown
-48.40%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VMTHF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$276.0M
-33.6% YoY
FY Net Income
-$182.0M
+51.3% YoY
Free Cash Flow
-$361.1M
+40.0% YoY
Revenue Growth
-36.5%
EPS Growth
+44.2%
Gross Margin
57.6%
Net Margin
-132.3%
Income statement
CNY
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 471M | 491M | 406M | 416M | 276M |
| Gross Profit | 368M | 389M | 314M | 324M | 227M |
| Operating Income | -347M | -590M | -650M | -279M | -179M |
| EBITDA | -613M | -548M | -999M | -324M | -146M |
| Net Income | -714M | -704M | -1.1B | -374M | -182M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 298M | 774M | 1.9B | 3.0B | 2.7B |
| Total Assets | 3.2B | 4.4B | 5.3B | 5.1B | 4.3B |
| Total Liabilities | 1.0B | 1.5B | 1.7B | 478M | 461M |
| Shareholder Equity | 2.2B | 2.9B | 3.6B | 4.5B | 3.8B |
| Total Debt | 369M | 826M | 900M | 71M | 33M |
| Net Debt | 71M | 52M | -980M | -2.9B | -2.7B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
237M
+48.1% YoY
Capital Expenditures
124M
+14.5% YoY
Free Cash Flow
361M
+40.0% YoY
Key ratios
Gross Margin
57.6%
Operating Margin
-112.5%
Net Margin
-132.3%
ROE
-21.1%
Debt / Equity
0.12x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.